12:00 AM
Jul 15, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Dificlir regulatory update

Germany's Federal Joint Committee (G-BA) said in a final benefit assessment for Dificlir fidaxomicin from Astellas that the drug has "significant" additional benefit over vancomycin to treat severe or recurrent Clostridium difficile-associated diarrhea (CDAD). In an April preliminary assessment, Germany's Institute for Quality and Efficiency in Healthcare...

Read the full 211 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >